Cabozantinib Could Be New Standard for Papillary RCC Cabozantinib Could Be New Standard for Papillary RCC
Cabozantinib outperforms the current standard of care for renal cell carcinoma (RCC), according to results from the Southwest Oncology Group 1500 trial.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
More News: Cancer & Oncology | Carcinoma | Health | Hematology | Kidney Cancer | Renal Cell Carcinoma